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Abstract: Background: The favorable influences of saffron supplementation on metabolic diseases 
have previously been shown. We aimed to assess the effects of saffron supplementation on blood pres­
sure in adults. Methods: A systematic search was performed in Scopus, Embase, and the Cochrane 
library databases to find randomized controlled trials (RCTs) related to the effect of saffron supple­
mentation on blood pressure in adults up to March 2021. The primary search yielded 182 publications, 
of which eight RCTs were eligible. Results: Our results showed that saffron supplementation resulted 
in a significant decrease in systolic blood pressure (weighted mean difference (WMD): −0.65 mmHg; 
95% CI: −1.12 to −0.18, p = 0.006) and diastolic blood pressure (DBP) (WMD: −1.23 mmHg; 95% CI: 
−1.64 to −0.81, p < 0.001). Moreover, saffron supplementation reduced DBP in a non-linear fashion, 
based on duration (r = −2.45, p-nonlinearity = 0.008). Conclusions: Saffron supplementation may 
significantly improve both systolic and diastolic blood pressure in adults. It should be noted that the 
hypotensive effects of saffron supplementation were small and may not reach clinical importance. 
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High blood pressure, also known as hypertension (HTN), is one of the most severe 
and prevalent global diseases, estimated to be implicated in 9.4 million global deaths annu­
ally [1]. The outcomes of empirical studies have indicated a positive correlation between 
high blood pressure (BP) and the incidence of chronic diseases, such as cardiovascular 
diseases [2], myocardial infarction [3], and kidney dysfunction [4,5]. To mediate such issues, 
controlling BP is essential. Healthy dietary habits and exercise are more preferable than 
medication, mainly related to the contraindications and side effects of pharmacological 
intervention [6–8]. Thus, the use of alternative herbal-based remedies is widespread [9], 
particularly since they generally relieve symptoms and cause significantly fewer side 
effects [10]. 
Empirical research has demonstrated the positive effect of medicinal plants, partic­
ularly saffron, on lowering BP [11]. Indeed, saffron is abundant in crocin, picrocrocin, 
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safranal, and crocetin [12], where such constituents are posited to confer positive effects on 
human health. 
Saffron stigmas have long been used as a spice and a food coloring, concomitant to 
saffron’s practicality in food supplements [13,14]. Medicinally, saffron is known for its 
antimicrobial, antioxidant [15], liver protection [16], anti-inflammatory [17,18], nervous 
system protection [19], fat amelioration [20–22], anti-depressant [23,24], and anti-cancer [25] 
properties. The effective role of saffron as an antioxidant is mainly due to crocin-1 and 
crocin-2 [26]. Saffron includes approximately 30% crocin, 5–15% picrocrocin, and 2.5% 
fugacious compounds, although the exact make-up varies by genus [27]. The results of both 
animal and human research have demonstrated the positive effect of saffron on various 
diseases [28,29]. In contrast, the positive impact of saffron on some metabolic diseases, such 
as hypertension and dyslipidemia in murine models, has also been indicated [12,30,31]. 
Although the results of some human-based studies indicate a positive effect of saffron on 
blood pressure, there is a distinct lack of an overarching consensus. Therefore, we aimed 
to conduct a systematic review and meta-analysis to determine the influence of saffron 
supplementation on BP in adults. 
2. Materials and Methods 
2.1. Literature Search 
The current study was conducted according to the PRISMA (preferred reporting items 
for systematic reviews and meta-analyses) guidelines [32]. Without any limitations on time 
and publication language, the following databases were used to identify suitable studies: 
PubMed, SCOPUS, EMBASE, Cochrane’s Library, and the ISI Web of Science. Search 
terms were related to saffron and its constituents (“saffron” OR “crocus” OR “crocin” OR 
“crocetin” “Crocus sativus Linn” OR “Safranal” OR “saffron”) AND (“Blood Pressure” OR 
“Hypertension” OR “systolic blood pressure” OR “diastolic blood pressure” OR “SBP” OR 
“DBP”). The search strategy identified articles published since journal inception, up to 
March 2021. 
2.2. Study Selection 
All of the articles were transformed into EndNote (version X7, for Windows, Thomson 
Reuters, Philadelphia, PA, USA) by a researcher (O.A.) who conducted a literature search. 
After the elimination of duplications, two independent authors (O.A. and P.K.) separately 
analyzed all titles and abstracts of the remaining articles, to ascertain whether these studies 
were eligible for our meta-analysis based on the inclusion criteria. Any dissimilar attitudes 
between the two investigators were settled by a panel discussion. 
2.3. Inclusion Criteria 
All of the studies needed to be RCTs, including crossover studies in adults (<18 years), 
in addition to the following criteria of a measured BP, and the use of any saffron component 
(e.g., whole saffron, standardized extracts, parts of saffron, or specific saffron-derived 
compounds). We also included interventions that used saffron combined with standard 
medications; however, combined interventions with other supplement ingredients were 
excluded. Finally, studies with observational and animal study designs, and acute inter­
ventions that were not in the form of randomized allocation or placebo-control groups, 
were excluded. 
2.4. Data Extraction 
The studies were independently screened and extracted by two authors, and a third 
author resolved disagreements. The following data were extracted using a standardized 
extraction form: first-named author, date, study design, the sample size in both intervention 
and control groups, total study period and follow-up, the characteristics of the target 
population, such as age, sex, body mass index (BMI), comorbidities, intervention features 
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(including dose, type, and duration of exposure), adverse events, and BP, before and after 
the intervention. 
2.5. Quality Assessment 
The quality assessments were performed using the Cochrane Collaboration’s tool [33] 
by two authors (O.A. and S.M.) independently. Cochrane Collaboration’s tool includes 
various different domains: sequence generation, allocation concealment, blinding of partic­
ipants and staff, blinding of the outcome assessment, missing outcome measures, selective 
outcome reporting, and other biases. For each item in the tool, the assessment of the risk of 
bias is in two parts. Each domain was categorized with a low, high, and unclear risk of bias. 
Based on Cochrane Collaboration’s tool, the quality of each publication was considered 
as good (low risk of bias for >2 domains), fair (low risk of bias for two domains), or weak 
(low risk of bias for <2 domains) [33]. 
2.6. Data Synthesis and Statistical Analysis 
The mean ± standard deviation (SD) of change in BP was used to calculate the effect 
size within intervention and control groups, using a random-effects model [34]. BP was 
expressed as the weighted mean difference (WMD) and 95% confidence intervals (CIs). 
The I-square and Q tests were used to assess the heterogeneity among studies. Subgroup 
analysis, based on saffron dosage, duration and type of intervention, and baseline systolic 
blood pressure (SBP) and diastolic blood pressure (DBP), was conducted to detect potential 
sources of heterogeneity [35]. The standard formula was applied to convert all other 
statistics to mean ± SD, while Hozo et al.’s system was applied to convert median and 95% 
CIs to mean and SD [36]. The following formula was used to convert standard errors of the √
mean (SEM): SDs by S.E.M × n (n is the number of participants in each group). 
All units were converted to the most frequently used unit. All analyses were per­
formed using the STATA version 12 (Stata Corporation, College Station, TX, USA), with 
statistical significance accepted, a priori, at p < 0.05. 
3. Results 
3.1. Study Selection 
Study selection was reported in Figure 1. The search strategy resulted in 182 studies 
through Scopus (n = 88), Embase (n = 59), and the Cochrane library (n = 35). Forty-four 
duplicated studies were excluded from our list, and 138 studies were screened to identify 
eligible studies. One-hundred and thirty studies were excluded, being animal-based 
(n = 15), review (n = 11), or unrelated studies (n = 104). Finally, after detailed scrutiny of 
the remaining articles, eight studies were included in our analysis. 
3.2. Study Characteristics 
Table 1 represents the characteristics of included articles, where all of them were 
randomized clinical trials (RCTs), published between 2008 and 2020, that were conducted 
in Iran [37–44]. The length of the intervention varied from 1 to 12 weeks, and the dosages 
of saffron supplementation were between 15 and 1000 mg. A cohort of 249 participants 
was collated in the intervention group, and 139 participants in the control group. The 
participants of these studies were classified as healthy volunteers [37], having type 2 
diabetes [41,43,44], or with schizophrenia [38], asthma [42], or metabolic syndrome [39,40]. 
All of the studies enrolled both sexes, and only one was exclusively conducted on men [38]. 
Four studies used crocin [38–40], and the other seven studies used saffron. Two different 
studies that utilized multiple interventions (saffron and crocin) [38] and dosages (200 and 
400 mg) [37] were considered as independent studies for the purposes of analysis. 
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Figure 1. Flowchart of study selection for inclusion of studies. 
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Table 1. Characteristics of included studies. 
Authors Publication Year 











IG CG IG 
Intervention/Control 
(Type and Dosage) 
Dose (mg) CG 
Modaghegh 
et al., 2008 
(A) [37] 
2008 IRAN R/DB/PL F/M 10 5 healthy volunteers 1 27.6 28.7 NR NR saffron 200 placebo 
Modaghegh 
et al., 2008 
(B) [37] 
2008 IRAN R/DB/PL F/M 10 5 healthy volunteers 1 28.7 28.7 NR NR saffron 400 placebo 
Fadai et al., 
2014 (A) [38] 2014 IRAN R/TB/PL M 20 21 
patients with 
schizophrenia 12 49.3 ± 7.1 48.1 ± 6.1 NR NR saffron 30 placebo 
Fadai et al., 
2014 (B) [38] 2014 IRAN R/TB/PL M 20 21 
patients with 
schizophrenia 12 48.1 ± 7.7 48.1 ± 6.1 NR NR crocin 30 placebo 
Kermani et al., 
2017 [39] 2017 IRAN R/DB/PL F/M 22 22 
metabolic 
syndrome 12 43.64 ± 11.17 42.59 ± 8.44 31.02 ± 5.45 30.48 ± 6.26 saffron 100 placebo 
Kermani et al., 
2017 [40] 2018 IRAN R/DB/PL F/M 24 24 
metabolic 
syndrome 6 53.8 ± 9.2 50.9 ± 8.8 29.9 ± 3.9 29.8 ± 5.3 crocin 100 placebo 
Ebrahimi et al., 
2019 [45] 2019 IRAN R/DB/PL F/M 40 40 
type 2 diabetic 
patients 12 55.2 ± 7.3 53 ± 10.6 29.3 ± 4.9 30.5 ± 4.7 saffron 100 placebo 
patients with 
Zilaee et al., 




8 41.27 ± 9.77 40.77 ± 10.07 26.84 26.84 saffron 100 placebo 
allergic asthma 
Behrouz et al., 
2020 [43] 2020 IRAN R/DB/PL F/M 23 22 
type 2 diabetic 
patients 12 57.08 ± 7.41 59.86 ± 9.46 30.64 ± 4.79 30.85 ± 3.19 crocin 15 placebo 
Azimi et al., 
2016 [44] 2016 IRAN R/SB/PL F/M 42 39 
type 2 diabetic 
patients 8 57.02 ± 1.0 53.64 ± 1.3 28.86 ± 0.2 28.40 ± 0.2 saffron 1000 placebo 
Abbreviations: R, randomized; DB, double-blind; SB, single-blind; PL, placebo; M, male; F, female; BMI, body mass index; IG, intervention group; CG, control group; NR, not reported. 
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3.3. The Effect of Saffron Supplementation on SBP 
The results of the pooled data from ten effect sizes [37–44] indicated that saffron 
supplementation reduced SBP (WMD: −0.65 mg/dL; 95% CI: −1.12 to −0.18, p = 0.006) 
compared with placebo, with moderate heterogeneity (I2 = 46.9%, p = 0.049) (Figure 2). 
Moreover, subgroup analysis showed that the saffron supplementation reduced SBP in all of 
the subgroups, except in those who had elevated SBP (>120 mmHg) (WMD: −0.47 mmHg; 
95% CI: −0.98 to 0.03, p = 0.068) (Table 2). 
Figure 2. The effects of saffron supplementation on SBP.
 
Table 2. The effects of saffron supplementation on blood pressure.
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Effect of saffron supplementation on SBP 
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Table 2. Cont. 
NO WMD (95%CI) p Value P Heterogeneity I2 (%) 
Effect of saffron supplementation on DBP 








0.66 (−2.50, 3.83) 






























−1.23 (−1.65, −0.81) 
−1.01 (−7.94, 5.92) 
−1.23 (−1.65, −0.81) 













Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure. 
3.4. The Effect of Saffron Supplementation on DBP 
Analysis of the eight effect sizes [37,39–44] indicated that saffron supplementation 
significantly reduced DBP (WMD: −1.23 mmHg; 95% CI: −1.64 to −0.81, p < 0.001) without 
significant heterogeneity (I2 = 0.0%, p = 0.928) (Figure 3). However, subgroup analysis 
showed that saffron supplementation could reduce DBP in participants with a baseline 
DBP ≥ 80 mmHg (WMD: −1.26 mmHg; 95% CI: −1.68 to −0.84, p < 0.001), in intervention 
durations less than 12 weeks (WMD: −1.25 mmHg; 95% CI: −1.68 to −0.83, p < 0.001), at 
dosages ≥100 mg per day (WMD: −1.23 mmHg; 95% CI: −1.65 to −0.81, p < 0.001), and 
interventions with crocin (WMD: −0.38 mmHg; 95% CI: −5.89 to 5.13, p < 0.001) (Table 2). 
Figure 3. The effects of saffron supplementation on DBP. 
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3.5. Non-Linear Dose-Response between the Doses and Duration of Saffron Supplementation and 
Blood Pressure 
Based on dose and duration, the dose-response analysis did not indicate any significant 
associations between saffron supplementation and changes in SBP. However, the dose-
response analysis showed that saffron supplementation significantly altered DBP based on 
duration (r = −2.45, p-nonlinearity = 0.008) in a non-linear fashion (Figures 4–7). 
Figure 4. Non-linear dose-response relationships between saffron supplementation and absolute 
mean differences. Dose-response relationships between saffron dosage and absolute mean differences 
in SBP. 
Figure 5. Non-linear dose-response relationships between saffron supplementation and absolute 
mean differences. Dose-response relationships between the duration of intervention and absolute 
mean differences in SBP. 
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Figure 6. Non-linear dose-response relationships between saffron supplementation and absolute 
mean differences. Dose-response relationships between the saffron dosage and absolute mean 
differences in DBP. 
Figure 7. Non-linear dose-response relationships are shown between saffron supplementation 
and absolute mean differences. Dose-response relationships are shown between the duration of 
intervention and absolute mean differences in DBP. 
3.6. Publication Bias 
Publication bias assessment, using Egger’s regression test and an asymmetric funnel 
plot, showed no evidence of publication bias (Table 3) in the meta-analysis regarding 
the influence of saffron supplementation on SBP (p = 0.543). Nevertheless, there was 
significant publication bias for DBP (p < 0.001), with funnel plots indicating the same result 
(Figures 8 and 9). Therefore, we conducted a trim and fill analysis for SBP. The results 
showed that when the publications reach 12, the publication bias changes significantly, but 
the overall results do not vary (WMD: −1.26 mmHg, CI: −1.67, −0.84; p < 0.001). 
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Table 3. Risk of bias assessment of the studies included in this meta-analysis. 
Random Allocation Selective Other Blinding of Blinding of Incomplete 
Study (Year) Sequence Conceal- Outcome Sources of Participants Outcome Outcome 
Generation ment Reporting Bias Personnel Assessors Data 
Modaghegh 
et al., L U L H L U L 
2008 [37] 
Fadai et al., 
2014 [38] L U H H L L L 
Azimi et al., 
2016 [44] L U L L H H L 
Kermani 
et al., L U L H L U L 
2017 [39] 
Kermani 
et al., L U L H L U L 
2018 [40] 
Ebrahimi 
et al., L U L L L U L 
2019 [45] 
Zilaee et al., 
2019 [42] L U L L L U L 
Behrouz 
et al., L U L L L U L 
2020 [43] 
Abbreviations: U; unclear risk of bias, L; low risk of bias, H; high risk of bias. 
Figure 8. Funnel plot for the effect of saffron supplementation on SBP. 
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Figure 9. Funnel plot for the effect of saffron supplementation on DBP. 
3.7. Sensitivity Analysis 
Sensitivity analysis for SBP and DBP showed that the overall estimate was not affected 
by sequential omission of any study. 
4. Discussion 
Despite some reports in the literature indicating the positive influence of saffron 
supplementation on BP, there was a distinct lack of an overarching consensus. Thus, in 
this meta-analysis, we assessed the effects of saffron supplementation on BP in adults. 
Accordingly, we found that saffron supplementation was associated with a decrease in 
SBP and DBP when compared to a control group. Moreover, the hypotensive effects of 
saffron in decreasing DBP were greater with longer supplementation durations, while this 
dose-response was not evident for SBP. 
It has been posited that some herbal medicines may be used for the prevention and 
treatment of chronic non-communicable diseases [46–48]. Indeed, some previous studies 
have reported that saffron supplementation and its components may reduce cardiovas­
cular risk factors by improving the lipid profile [40,49,50], glycemic profile [50,51], and 
inflammation [51], as well as decreasing waist circumference [45,52]. Indeed, our results 
indicated improvements in BP variables, including SBP and DBP, and the hypotensive 
effects of saffron may be related to its components, including crocin, picrocrocin, safranal, 
and crocetin [12,53]. 
Our findings revealed that saffron supplementation has a small but significant effect 
on improving BP. Saffron may exert its antihypertensive effects through several mech­
anisms. For instance, animal-based studies have shown that saffron extract increases 
serum concentrations of nitric oxide (NO) [54,55]. Tang et al. indicated that crocetin 
significantly restored the endothelium-dependent relaxation of the thoracic aorta in hy­
percholesterolemic rabbits [56]. Moreover, Tang et al. also posited that these effects might 
be mediated by increasing endothelial NO synthase (eNOS) activity, leading to the el­
evation of NO production. In addition, saffron supplementation possesses numerous 
antioxidant properties, combats reactive oxygen species [57,58], and can enhance other 
antioxidant enzymes, such as catalase and superoxide dismutase [59,60], thereby protect­
ing endothelial cells from oxidative damage and regulating BP. It has also been shown 
that saffron can act as a protective agent against cardiovascular disease by attenuating 
the NF-kappa B pathway [61,62]. Therefore, the anti-inflammatory effects of saffron may 
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be another putative method by which hypotensive effects are exerted [63]. It has previ­
ously been indicated that crocetin can significantly down-regulate intercellular adhesion 
molecule-1 (ICAM-1) protein expression [64]. Indeed, endothelial dysfunction and an 
increased expression of ICAM-1 play roles in the initiation of the inflammatory process, 
which in turn has been reported to affect the renin-angiotensin system and contribute 
to hypertension [65]. Furthermore, in vitro and in vivo studies have demonstrated that 
saffron supplementation modulates adiponectin expression and secretion [66,67]. Evidence 
suggests that adiponectin has an influential role in regulating BP, and may reduce BP 
through anti-inflammatory, anti-atherogenic, and insulin sensitivity effects, concomitant 
to reversing salt-induced hypertension [68]. Overall, these findings indicate that saffron 
supplementation might be regarded as a potentially useful supplement for BP regulation. 
However, because of the small effect size, it should only be recommended with caution. 
Despite the novelty of the results presented in this manuscript, our results should be 
interpreted while taking into consideration the following limitations. First, since all RCTs 
lasted less than three months, our analysis could not determine the long-term effects of 
saffron on BP. Although challenging to conduct, long-term research will help determine if 
the transient changes, or lack thereof, persist over time. Second, all studies were conducted 
in Iran, and this may represent a source of bias in our study. Indeed, this is out of the 
operational control of the study; however, we advocate that comparable studies should 
be conducted in a variety of geographical locations, so that this potential source of bias 
may be examined. Third, in most of the included studies, BP was reported as a secondary 
outcome, potentially harming the fidelity of measurements. 
In the literature, saffron supplementation was associated with decreases in SBP and 
DBP when compared to a control group. Moreover, the hypotensive effects of saffron in 
reducing DBP but not SBP appeared to respond in a dose-response manner, whereby longer 
intervention durations were associated with a more significant decrease. However, it should 
be noted that the hypotensive properties of saffron supplementation were small and may 
not reach clinical importance. It has been mentioned that the minimal clinically important 
difference (MCID) is classified as clinically important, and is considered the smallest effect 
required to produce clinically important results [69]. The data for MCID regarding BP 
is limited; however, several studies have confirmed that the risk of hypertension, CHD, 
and stroke could be decreased whenever they saw reductions of ≥ 2 mmHg SBP and 
DBP [70–72]. Since WMD of the effects of saffron supplementation on both SBP and DBP 
is less than the MCID, we can consider that the beneficial effects of saffron on BP are not 
clinically significant. Further long-term and high-quality RCTs are needed to evaluate 
further and confirm the integrity of these findings. 
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